NasdaqGS:UTHRBiotechs
Is United Therapeutics (UTHR) Undervalued After Its Phase 3 Ralinepag Results?
United Therapeutics (UTHR) stock is in focus after the company reported statistically significant phase 3 ADVANCE OUTCOMES results for its investigational PAH therapy ralinepag, with full data recently published in The Lancet.
See our latest analysis for United Therapeutics.
The latest ralinepag data and board appointment of Dr. Victor Dzau come as United Therapeutics trades at US$524.70, with the share price return up 5.63% year to date but the 90-day share price return down 8.16%. Over a...